June 1, 2023 07:28 AM EDT
Bioregnum

Who's con­fi­dent­ly in­vest­ing in biotech star­tups dur­ing these tense days? We've got some an­swers

John Carroll

Editor & Founder

We’ve got a change­up to our event sched­ule in Boston next week, where we’ll be do­ing a mix of live/stream­ing events at our base …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

‘Just the be­gin­ning’: No­bel Prizes show the AI era has ar­rived in biotech

Ex­clu­sive Q&A: FDA's prin­ci­pal deputy com­mis­sion­er on tak­ing over for Califf, ad­comms, ac­cel­er­at­ed ap­provals and more

CMS looks to $2 out-of-pock­et cap for some com­mon­ly used gener­ic drugs

AI biotech in­sitro part­ners with Lil­ly on meta­bol­ic dis­ease drugs

Zealand Phar­ma hit with sec­ond CRL for glucagon re­cep­tor ag­o­nist

GSK to pay up to $2.2B to set­tle al­most all Zan­tac-re­lat­ed court cas­es

A service from the Financial Times